R. S. Baric

Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination

This study compares IgG antibody responses from SARS-CoV-2 infection, vaccination, and hybrid immunity, finding that hybrid immunity retains the imprint of the initial exposure and enhances antibody breadth and affinity.

Efficacy of Host Cell Serine Protease Inhibitor MM3122 against SARS-CoV-2 for Treatment and Prevention of COVID-19

This paper demonstrates that MM3122, a host cell serine protease inhibitor, effectively inhibits SARS-CoV-2 replication and reduces disease severity in mice, both prophylactically and therapeutically.

ACE2 from Pipistrellus abramus bats is a receptor for HKU5 coronaviruses

The paper identifies ACE2 as a receptor for HKU5 coronaviruses from Pipistrellus abramus bats and investigates receptor tropism across merbecovirus clades.

Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV

This study develops MERS-CoV vaccines using a protein nanoparticle platform, showing they induce strong neutralizing antibodies and protect mice against MERS-CoV challenge.

Prolonged airway explant culture enables study of health, disease, and viral pathogenesis

This study develops methods to culture human and animal airway explants for at least 14 days, preserving tissue architecture and enabling study of health, disease, and viral infection.

Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates

Non-stabilized SARS-CoV-2 Spike mRNA vaccination in macaques induces B cell lineages targeting conserved epitopes on Omicron variants or cross-neutralizing epitopes on Sarbecoviruses.

Vaccine-mediated protection against merbecovirus and sarbecovirus challenge in mice

This study develops a trivalent RBD nanoparticle vaccine that protects mice against both merbecovirus and sarbecovirus challenges, including SARS-CoV, MERS-CoV, and SARS-CoV-2.

N4-Hydroxycytidine/Molnupiravir Inhibits RNA-Virus Induced Encephalitis by Producing Mutated Viruses with Reduced Fitness

This study shows that N4-hydroxycytidine and its prodrug molnupiravir reduce RNA-virus-induced encephalitis by producing less fit viruses with G-to-A and C-to-U mutations.

Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions

This study shows non-neutralizing SARS-CoV-2 antibodies protect mice from severe disease via Fc-mediated effector functions, reducing viral load and lung damage.

Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential

This study evaluates the antiviral efficacy of GS-5245 against multiple SARS-CoV-2 variants and other coronaviruses, showing broad in vitro activity and protective effects in animal models.

A semi-quantitative, rapid, point of care SARS-CoV-2 serologic assay predicts neutralizing antibody levels

This paper introduces a semi-quantitative lateral flow assay that correlates with neutralizing antibody levels in SARS-CoV-2 recovered individuals.

Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2

This study identifies potent pan-sarbecovirus neutralizing antibodies from vaccinated macaques, showing broad neutralization against SARS-CoV-2 variants and related viruses.

Targeting Spike Glycans to Inhibit SARS-CoV2 Viral Entry

This study shows that BOA, a lectin, binds to SARS-CoV-2 Spike glycans and inhibits viral entry at nanomolar concentrations, effective against variants of concern.

Fc mediated pan-sarbecovirus protection after alphavirus vector vaccination

This study shows that non-neutralizing antibodies targeting FcR4 and spike S2 provide cross-protection against sarbecoviruses after alphavirus vector vaccination.

Fc-gamma receptor-dependent antibody effector functions are required for vaccine protection against infection by antigenic variants of SARS-CoV-2

This study shows that Fc-gamma receptor-dependent antibody effector functions are necessary for vaccine protection against antigenic variants of SARS-CoV-2, including Omicron.

Host network-based discovery of critical regulators of innate immunity, virus growth, and pathogenesis in influenza virus infection

The paper identifies novel innate immune regulators affecting influenza virus replication and pathogenesis through experimental validation of network model predictions.

A Multitrait Locus Regulates Sarbecovirus Pathogenesis

The paper identifies a multitrait locus on mouse Chromosome 9 that regulates SARS-CoV, SARS-CoV-2, and bat sarbecovirus disease severity, with candidate genes CCR9 and CXCR6.

Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease

The paper identifies broadly neutralizing antibodies targeting the S2 region of betacoronavirus spikes that protect against SARS-CoV-1, SARS-CoV-2, and MERS-CoV.

Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains

This study identifies a biparatopic VH domain that neutralizes SARS-CoV-2 VOCs, including Omicron, with high potency in vitro and in a mouse model.

Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine

This study shows a nanoparticle vaccine induces broad neutralizing antibodies against multiple SARS-CoV-2 variants and protects non-human primates and mice from viral challenges.

Distinct genetic determinants and mechanisms of SARS-CoV-2 resistance to remdesivir

This study identifies distinct mutations in SARS-CoV-2's RdRp that confer remdesivir resistance, showing their biochemical mechanisms and transferability to other coronaviruses.

Host kinase CSNK2 is a target for inhibition of pathogenic β-coronaviruses including SARS-CoV-2

The paper shows that inhibiting the kinase CSNK2 blocks replication of several beta-coronaviruses, including SARS-CoV-2, by preventing viral entry.

Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice

This study tests FDA-approved kinase inhibitors against SARS-CoV-2 in vitro and in vivo, finding that vandetanib reduces inflammatory cytokines and mitigates lung inflammation in infected mice without reducing viral load.

A global map of the Zika virus phosphoproteome reveals host-driven regulation of viral budding and cytopathogenicity

This study maps host-driven post-translational modifications on the Zika virus proteome, identifies key phosphosites, and shows how an FDA-approved kinase inhibitor blocks viral growth.

Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.

This paper evaluates the therapeutic efficacy of GS-621763, an oral prodrug of remdesivir, against SARS-CoV-2 in mice, showing reduced viral load and improved lung function.

Targeted isolation of panels of diverse human protective broadly neutralizing antibodies against SARS-like viruses

This study isolates a panel of broadly neutralizing antibodies against SARS-like viruses from donors, showing effectiveness against multiple variants including Omicron.

Thiol-based mucolytics exhibit antiviral activity against SARS-CoV-2 through allosteric disulfide disruption in the spike glycoprotein

This study shows thiol-based mucolytics inhibit SARS-CoV-2 by disrupting disulfides in the spike protein, reducing ACE2 binding and viral infection.

SARS-CoV-2 mRNA Vaccine Induces Robust Specific and Cross-reactive IgG and Unequal Strain-specific Neutralizing Antibodies in Naïve and Previously Infected Recipients

This study examines antibody responses to SARS-CoV-2 mRNA vaccines in naive and previously infected individuals, finding robust IgG and varying neutralizing antibody levels against different variants.

Protective efficacy of rhesus adenovirus COVID-19 vaccines against mouse-adapted SARS-CoV-2

This study evaluates the protective efficacy of rhesus adenovirus serotype 52 vaccines against a mouse-adapted SARS-CoV-2 strain, showing robust antibody responses and protection against viral replication and disease.

Common Mechanism of SARS-CoV and SARS-CoV-2 Pathogenesis across Species

The paper identifies host susceptibility loci for SARS-CoV and SARS-CoV-2 using GWAS and Collaborative Cross datasets, validating CCR9 as a key regulator of severe disease outcomes across species.